QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Plasma-Derived Medicinal Products—Classification and Pharmacovigilance

Test your understanding of the concepts covered by Plasma-Derived Medicinal Products: Classification and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A safety report describes an event after administration of an unspecified 'immunoglobulin' even though several products are used at the site. What is the principal pharmacovigilance concern?

The report must be rejected because immunoglobulins are not medicinal products The lack of precise product identity may prevent product-specific signal assessment The event should automatically be attributed to the entire immunoglobulin class Product identity is relevant only for quality complaints, not adverse-event reports

Question 2 of 10 Which record set would best support reconstruction of the reasoning behind a suspected product-quality or infectious-safety assessment?

Only the final conclusion Only the product label and standard operating procedure Case data, exposure and batch information, quality findings, alternative explanations, uncertainty and the rationale for actions Only the number of reports received during the period

Question 3 of 10 Which statement best describes the relationship between general GVP requirements and plasma-derived product surveillance?

Plasma-derived products require an entirely separate pharmacovigilance system General GVP processes apply, supplemented by product-specific understanding and controls Only quality legislation applies because the products originate from plasma General GVP is unnecessary when a plasma master file exists

Question 4 of 10 A cluster of adverse events is reported predominantly for one batch. What is the most appropriate next step?

Conclude immediately that the batch is defective Ignore the cluster because batch association cannot be relevant to pharmacovigilance Initiate a proportionate integrated assessment involving clinical, pharmacovigilance and quality information Withdraw all plasma-derived products automatically

Question 5 of 10 What is the most appropriate purpose of traceability controls across prescribing, dispensing and administration?

To reconstruct clinically meaningful exposure when investigating a safety question To prove causality for any event occurring after treatment To eliminate the need for medical assessment To require complete reconstruction of every manufacturing detail for every case

Question 6 of 10 Why should plasma-derived medicinal products be distinguished from blood or plasma used directly for transfusion?

They are subject to different regulatory frameworks and have different product identities and manufacturing pathways Transfusion products cannot cause adverse reactions Plasma-derived medicinal products are always recombinant Only transfusion products require traceability

Question 7 of 10 An increase in reports follows a widely publicised safety concern, but no corresponding change in clinical presentation or exposure is evident. What should signal assessors consider?

Publicity or increased awareness may have stimulated reporting without proving increased clinical risk The increase confirms a manufacturing defect The reports should be excluded because stimulated reporting is never informative The product should automatically be classified as having a new identified risk

Question 8 of 10 What is the purpose of combining starting-material controls with viral removal or inactivation steps?

To create layered barriers that reduce infectious risk at different stages of the supply chain To demonstrate that post-authorisation infectious surveillance is unnecessary To ensure that all infectious agents can be identified in every donation To replace finished-product quality control

Question 9 of 10 Why should reporting counts for a plasma-derived product generally be interpreted with an exposure denominator where possible?

A high number of reports may simply reflect extensive use Denominators eliminate all reporting bias Rare serious events are unimportant when report counts are low Report counts directly measure incidence regardless of exposure

Question 10 of 10 Which approach best prevents premature conclusions during signal assessment?

Treat every temporal association as evidence of causality Separate evidence of occurrence after exposure, evidence of product contribution and the likely mechanism Classify all severe events as confirmed risks Focus exclusively on disproportionality statistics

QPPV.com

Knowledge Assessment: Plasma-Derived Medicinal Products—Classification and Pharmacovigilance

Cookie Settings